Rectal Cancer Clinical Trial
The study aims to evaluate the efficacy of percutaneous tibial nerve stimulation (PTNS)
associated with conservative therapy (arm A) for the treatment of low anterior resection
syndrome (LARS) compared with only conservative therapy (arm B).
The secondary aims are the evaluation of the following parameters:
- Effect of PTNS on manometric parameters
- Effect of PTNS on quality of life
- Effect of PTNS on the severity of fecal incontinence and / or obstructed defecation
- Safety of PTNS
The study is a prospective randomized clinical trial that compares two treatments in
patients with LARS:
Arm A: PTNS + conservative treatment (based on predominant symptom) Arm B: only conservative
treatment
The study is divided into two phases:
1. PRETREATMENT PHASE
The patients with LARS score ≥ 21 after anterior resection of the rectum with
sphincter-saving surgery for rectal cancer, will be submitted during the first visit of
the study to :
- Collection of personal data
- Collection of medical records
- Collection of data relating to the intervention of anterior resection of the
rectum
- Verification of the criteria for inclusion / exclusion
- Collection of informed consent
- Administration of the questionnaires European Organisation for Research and
Treatment of Cancer - Quality of Life Questionnaire Cancer 30 (EORTC QLQ-C30),
European Organisation for Research and Treatment of Cancer - Quality of Life
Questionnaire Colorectal 38 (EORTC QLQ-CR38), Faecal incontinence severity index
(FISI); Fecal incontinence quality of life questionnaire (FIQL), Obstructed
defaecation syndrome (ODS) score questionnaire and Constipation-related quality of
life questionnaire (CRQoL)
- Endoanal ultrasound
- Anorectal manometry
2. PHASE OF TREATMENT During the treatment phase, data related to the treatment and any
treatment related-complications will be recorded on a special form Bowel function and
quality of life will be assessed using the same questionnaires at the end of treatment.
Even anorectal manometry will be repeated at the end of treatment.
It is expected to enroll approximately 12 patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |